NBP
I-Mab · Healthcare · Biotechnology
Last
$3.28
−$0.00 (−0.03%) 4:00 PM ET
After hours $3.32 +$0.05 (+1.38%) 2:14 AM ET
Prev close $3.28
Open $3.20
Day high $3.37
Day low $3.06
Volume 883,996
Avg vol 567,259
Mkt cap
$378.15M
Sector
Healthcare
AI report sections
NBP
I-Mab
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
+118% (Above avg)
Vol/Avg: 2.18×
RSI
41.83 (Neutral)
Neutral (40–60)
MACD momentum
Intraday
-0.00 (Weak)
MACD: -0.01 Signal: -0.00
Short-Term
+0.01 (Strong)
MACD: -0.14 Signal: -0.15
Long-Term
-0.01 (Weak)
MACD: -0.21 Signal: -0.20
Intraday trend score 51.00

Latest news

NBP 3 articles Positive: 3 Neutral: 0 Negative: 0
Positive GlobeNewswire Inc. • Na
NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026

NovaBridge Biosciences announced its inclusion in the Nasdaq Biotech Index effective December 19, 2025, and will ring the Nasdaq opening bell on January 2, 2026. The company highlighted this milestone as recognition of its strategic vision and pipeline strength as a global biotechnology platform focused on developing innovative medicines.

NBP Nasdaq Biotech Index givastomig VIS-101 biotechnology clinical development 4-1BB bispecific antibody gastric cancer
Sentiment note

The company achieved a notable milestone by being included in the Nasdaq Biotech Index, which enhances visibility and validates its position as an industry leader. Leadership expressed confidence in the company's strategic vision and pipeline strength, and the opening bell ringing ceremony represents positive market recognition.

Positive GlobeNewswire Inc. • Novabridge Biosciences
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO

NovaBridge Biosciences and ABL Bio reported positive Phase 1 dosing study results for ragistomig, a 4-1BB X PD-L1 bispecific antibody designed to treat patients resistant to checkpoint inhibitors, with extended dosing interval showing strong anti-tumor efficacy and improved safety profile.

NBP ragistomig bispecific antibody checkpoint inhibitors cancer treatment immunotherapy
Sentiment note

Reported promising clinical trial results, expanded dosing options, and potential advancement in cancer treatment

Positive GlobeNewswire Inc. • Novabridge Biosciences
NovaBridge’s Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

NovaBridge's subsidiary Visara appointed Dr. Cadmus C. Rich as Chief Medical Officer and Dr. Carlos Quezada-Ruiz as Scientific Advisory Board Chair to advance VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2 for treating retinal diseases.

NBP ophthalmology VIS-101 retinal diseases wet AMD clinical development
Sentiment note

Company is expanding leadership team with experienced professionals and advancing promising drug candidate VIS-101

News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal